248 results on '"Lindegren, Sture"'
Search Results
2. Behaviour, use and safety aspects of astatine-211 solvated in chloroform after dry distillation recovery
3. Improved syntheses of P2X7 ligands based on substituted benzyl amide of pyroglutamic acid motif labelled with iodine-123 or iodine-125
4. Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted a-Therapy of Prostate Cancer.
5. Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer
6. A Novel Method for Real-Time Quantification of Radioligand Binding to Living Tumor Cells In Vitro
7. Pretargeted Alpha Therapy of Disseminated Cancer - Combining Click Chemistry and Astatine-211
8. Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors
9. Towards elucidating the radiochemistry of astatine – Behavior in chloroform
10. Improved syntheses of P2X7 ligands based on substituted benzyl amide of pyroglutamic acid motif labelled with iodine-123 or iodine-125.
11. P-281 - Pretargeted Alpha Therapy of Disseminated Cancer - Combining Click Chemistry and Astatine-211
12. Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
13. Astatine-211 based radionuclide therapy: Current clinical trial landscape
14. Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients
15. N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides
16. Estimating the Risk for Secondary Cancer After Targeted α-Therapy with211At Intraperitoneal Radioimmunotherapy
17. Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211.
18. Theranostic tetrazines: radiosynthesis and evaluation of aromatic 18F/211At pair highly reactive tetrazines for pretargeted bioorthogonal PET imaging and targeted alpha-therapy
19. Astatine-211 based PSMA-inhibitors for targeted alpha-therapy of prostate cancer
20. Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy.
21. Astatine-211 labeling: a study towards automatic production of astatinated antibodies
22. Covalent core-radiolabeling of polymeric micelles with 125I/211At for theranostic radiotherapy
23. Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure
24. Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy
25. Covalent core-radiolabeling of polymeric micelles with 125I/211At for theranostic radiotherapy.
26. Estimating the risk for secondary cancer following targeted alpha therapy with astatine-211 intraperitoneal radioimmunotherapy.
27. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb
28. Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer
29. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab′) 2: therapeutic efficacy and myelotoxicity
30. Quantified Cell Binding of Astatinated Immunoconjugates on Ovarian Cancer Cell Spheroids by Alpha Camera Imaging
31. Astatine-211: The Chemistry Infrastructure
32. Intraperitoneal Alpha-emitting Radio Immunotherapy with Astatine-211 in Relapsed Ovarian Cancer; Long-term Follow-up with Individual Absorbed Dose Estimations
33. Estimation of Long-term Risks for Cancer Induction following Adjuvant Targeted Alpha Therapy with Curative Intent
34. P-017 - Astatine-211 based PSMA-inhibitors for targeted alpha-therapy of prostate cancer
35. P-008 - Theranostic tetrazines: radiosynthesis and evaluation of aromatic 18F/211At pair highly reactive tetrazines for pretargeted bioorthogonal PET imaging and targeted alpha-therapy
36. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior
37. Multifunctional Clickable Reagents for Rapid Bioorthogonal Astatination and Radio‐Crosslinking
38. Front Cover: Multifunctional Clickable Reagents for Rapid Bioorthogonal Astatination and Radio‐Crosslinking (ChemPlusChem 7/2019)
39. Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
40. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields
41. Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations.
42. Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes
43. Abstract 834: Formation of DNA double-strand breaks in colon tumors after targeted alpha therapy with211At-mAb
44. BIOTINYLATED AND CHELATED POLY-L-LYSINE AS EFFECTOR FOR PRETARGETING IN CANCER THERAPY AND IMAGING
45. Intraperitoneal a-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations.
46. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with 211At-MX35-F(ab′)2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival
47. 17AAG-induced internalisation of HER2-specific Affibody molecules
48. Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates
49. Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors
50. Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.